Premium
Photodynamic therapy of locoregional breast cancer recurrences using a chlorin‐type photosensitizer
Author(s) -
Wyss Pius,
Schwarz Viola,
DoblerGirdziunaite Diana,
Hornung Rene,
Walt Heinrich,
Degen Andrea,
Fehr Mathias
Publication year - 2001
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.1400
Subject(s) - photodynamic therapy , photosensitizer , medicine , breast cancer , radiation therapy , surgery , chlorin , cancer , photochemistry , chemistry , organic chemistry
Chest wall recurrences are a frequent problem in patients treated by mastectomy for breast cancer. Surgery and ionizing radiation are established treatment modalities in these cases. Photodynamic therapy (PDT) provides an alternative treatment modality using a photosensitizer and laser light to induce selective tumor necrosis. PDT was performed as compassionate use in 7 patients aged 57.6 years (±12.6 SD). A total of 89 metastatic skin nodes were treated in 11 PDT sessions. As photosensitizer meta‐tetra(hydroxyphenyl)chlorin (m‐THPC) was applied intravenously. Patients ( n = 3) photosensitized with a drug dose of 0.10 mg/kg bodyweight were irradiated 48 hr after drug application at a lightdose of 5 J/cm 2 . Patients ( n = 4) were illuminated by an optical dose of 10 J/cm 2 96 hr after photosensitization with 0.15 mg/kg. Laser light at a wavelength of 652 nm was generated by a diode laser and applied by a front lens light diffuser using a fluence rate of 20–25 mW/cm 2 . PDT using m‐THPC resulted in complete response in all patients. Response to treatment did not differ when using the 2 different drugdose protocols. Healing time depended mainly on the size of the illumination field but not on the lightdose. Pain score usually raised 1 day after PDT and lasted at higher levels for about 10 days. Healing time usually ranged between 8–10 weeks. Photodynamic technique offers a minimal‐invasive, outpatient treatment modality for recurrent breast cancer on the chest wall with few side effects, high patient's satisfaction and with possible repetitive application. © 2001 Wiley‐Liss, Inc.